CD3E Antibodies

CD3E antibodies are specialized antibodies that target the CD3 epsilon (CD3ε) protein, a crucial component of the CD3 complex found on the surface of T cells. The CD3 complex, which also includes CD3γ, CD3δ, and CD3ζ chains, is associated with the T cell receptor (TCR) and plays a vital role in T cell activation, signaling, and immune response. CD3E is essential for the assembly, surface expression, and function of the TCR complex.

Content: CD3E antibodies can be used to target CD3ε in various applications, including:

• T Cell Identification and Isolation: CD3E is a reliable marker for identifying T cells, as the CD3 complex is expressed on all mature T cells, including both CD4+ helper T cells and CD8+ cytotoxic T cells. Anti-CD3E antibodies are widely used in research and clinical settings to identify, isolate, and quantify T cell populations from blood and other tissues.
• T Cell Activation: CD3E is critical for T cell receptor (TCR) signaling. Engagement of the TCR complex by antigens leads to the phosphorylation of CD3 chains, initiating downstream signaling pathways that activate T cells. Anti-CD3E antibodies can be used to mimic antigen binding and stimulate T cell activation, making them essential tools for studying T cell signaling and for expanding T cells ex vivo for research or therapeutic purposes.

Applications: CD3E antibodies are widely used in various research and clinical applications, including:

• T Cell Activation Assays: Anti-CD3E antibodies can be used to stimulate T cells in vitro, mimicking antigen recognition. When used in combination with co-stimulatory antibodies (e.g., anti-CD28), these antibodies can induce robust T cell activation, proliferation, and cytokine production. 
• Western Blotting (WB): To detect CD3E protein levels in cell lysates. Western blotting with CD3E antibodies can help in studying T cell receptor expression and the impact of various treatments on T cell activation and signaling pathways.
• Therapeutic Applications: Anti-CD3E antibodies, such as muromonab-CD3 (OKT3), were among the first monoclonal antibodies used therapeutically to treat acute organ transplant rejection. By binding to the CD3 complex on T cells, these antibodies can trigger T cell depletion, reducing the immune response against transplanted tissues. 

CD3E antibodies are indispensable tools in immunology, oncology, and clinical diagnostics. They allow researchers to dissect the mechanisms of T cell activation, study immune responses, and develop innovative therapies for a range of diseases, including cancer and autoimmune disorders.